17-Alpha Estradiol - Another Top Anti-Aging Drug

50μg to 70mg is a massive range. How would you even go about measuring 50 μg from a powder?

A very accurate laboratory $cale.

In one of the papers they mix the powder in distilled water for the clinical study. Different levels of dilution of the solution with distilled water will result in different quantities of 17-alpha estradiol being consumed for a given quantity. Not too hard to figure out…

3 Likes

More good safety news on 17-alpha estradiol:

17α-estradiol does not adversely affect sperm parameters or fertility in male mice: implications for reproduction-longevity trade-offs

Despite an abundance of data indicating that 17α-E2 attenuates several hallmarks of aging in male rodents, very little is known with regard to its effects on feminization and fertility. In these studies, we evaluated the effects of 17α-E2 on several markers of male reproductive health in two independent cohorts of mice. In alignment with our previous reports, chronic 17α-E2 treatment prevented gains in body mass, but did not adversely affect testes mass or seminiferous tubule morphology. We subsequently determined that chronic 17α-E2 treatment also did not alter plasma 17β-estradiol or estrone concentrations, while mildly increasing plasma testosterone levels.

We conclude that chronic treatment with 17α-E2 at the dose most commonly employed in aging research does not adversely affect reproductive fitness in male mice, which suggests 17α-E2 does not extend lifespan or curtail disease parameters through tradeoff effects with reproduction.

6 Likes

More good news on 17 alpha-estradiol for males:

17α-estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice

Estrogen signaling is protective against chronic liver diseases…We sought to determine if 17α-estradiol (17α-E2), a naturally-occurring diastereomer of 17β-E2, could attenuate liver fibrosis.

Findings: We found that 17α-E2 significantly reduced collagen synthesis rates and increased collagen degradation rates, which was mirrored by declines in transforming growth factor β1 (TGF-β1) and lysyl oxidase-like 2 (LOXL2) protein content in liver. These improvements were associated with increased matrix metalloproteinase 2 (MMP2) activity and suppressed stearoyl-coenzyme A desaturase 1 (SCD1) protein levels, the latter of which has been linked to the resolution of liver fibrosis. We also found that 17α-E2 increased liver fetuin-A protein, a strong inhibitor of TGF-β1 signaling, and reduced pro-inflammatory macrophage activation and cytokines expression in the liver.

Interpretation: We conclude that 17α-E2 reduces fibrotic burden by suppressing HSC activation and enhancing collagen degradation mechanisms. Future studies will be needed to determine if 17α-E2 acts directly in hepatocytes, HSCs, and/or immune cells to elicit these benefits

Full Paper PDF Here:

4 Likes

Seems like 17 alpha-estradiol might be a good match for a keto diet…

17α-Estradiol Mitigates the Negative Effects of High-Fat Feeding in Both Male and Female Mice

Although the effects of 17α-E2 on liver and adipose tissue are well described, potential benefits in skeletal muscle are unknown. The objective of this study was to determine if 17α-E2 can mitigate the negative effects of a high-fat diet (HFD) on skeletal muscle metabolism. In addition, we sought to determine if there were sex differences in these responses.

17α-E2 reduced insulin resistance in males and females. 17α-E2 reduced the expression of IL-6 and TNFα in males, but 17α-E2 did not change cytokine expression in females. There was no difference in gastrocnemius ORO staining in the males or females. 17α-E2 supplementation did not change quadricep triglycerides in males. However, females on 17α-E2 had significantly lower quadricep triglycerides compared to HFD. These results suggest that long term 17α-E2 supplementation ameliorates the effects of a HFD on skeletal muscle in both males and females but in a sex dimorphic manner.

https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.2022.36.S1.R4550#.Yq97qym4c-k.twitter

7 Likes

17α-E2 is definitely up there with acarbose as next on my anti-aging list. I wanted to give rapamycin a full year before adding another major intervention. I am on the keto diet, so this might be the key factor in deciding to try 17α-E2.

2 Likes

I would not risk feminization features. But I have an idea for this as Alzheimer’s was my white whale previously.

There is a completely different alternative to pretty much completely avoid the feminizing effects of 17-beta-estradiol “contamination” using a brain-selective pro-drug that crosses the BBB. The downside is it won’t have desired 17-alpha estradiol systemic effects, but I suspect it has promise for decreasing age-related amyloid-beta and pro-cognitive effects with neuroprotective/decreased neuroinflammatory properties. That memory boost in mice seemed pretty decent.

Meet alpha-DHED (>98%):

https://www.sigmaaldrich.com/US/en/product/sigma/sml2396

6 Likes

@tongMD Re DHED, brain ONLY pathway, very interesting molecule.

Do you have other “white whale” thoughts other than summary below, or your original meaning?

I see no clinical trials registered.

Here is a summary of DHED/AD (2016)

One notable comment: "Roberta Diaz Brinton, PhD, has proposed the “healthy cell bias” hypothesis of estrogen actions in the brain, which suggests that estrogens are protective in healthy cells but may be harmful in diseased states. For example, in cell culture, 17β-estradiol is protective when applied prior to or during Aβ42 insult. It is not protective if applied after—and exacerbates Aβ42-induced apoptosis. If this theory is true, DHED may only be protective at an early stage of AD (or before the appearance of neuropathology).

A more recent 2019 paper, transgenic AND ovariectomized mice (female Tg2576 transgenic AD mice were ovariectomized and then treated by implanting Alzet osmotic mini pumps containing DHED or vehicle subcutaneously for 8 weeks):

" Evidence showed that AD is not restricted to neurodegenerative process but strongly interacts with immunological mechanisms in the brain (Zhang et al. 2013). Cytokines including TNF-α, IL-6, and IL-1β are associated with increased Aβ in aging Tg2576 mice, so we analyzed the RNA and protein levels of TNF-α, IL-6, and IL-1β. We observed a significantly decreasing of TNF-α, IL-6, and IL-1β in the hippocampus. These data demonstrate that DHED might involve in inhibiting the inflammatory pathway to influence Aβ level in hippocampus. Taken together, our findings uncovered a new mechanism for DHED to improve the cognitive function of AD mice and may provide a viable therapy to treat AD."

2 Likes

One thing that’s puzzling about the potential translatability of 17 alpha is that we have a lot (relatively) of people who were assigned male at birth (AMAB) who are taking 17 beta estradiol for gender affirming therapy without any sign of life extension in this population. There’s even some mixed evidence that 17 beta estradiol increases CVD risk in those AMAB.

Blagosklonny raised similar questions in a couple of tweets:

2 Likes

If these TM2Fs were assigned biological males at birth and got tons of 17 beta-E2 at the level intended for females (and androgen blockers ie spirinolactone), I would assume applicability is extremely slim. Not to mention, there are a bunch of confounders like obesity/medical conditions (pre hormone therapy), stress, HIV/other STI (seen enough advanced HIV induced cardiomyopathies), and drug use.

There are huge estrogenic potency differences (17alpha E2 is very weak “feminizer”) and massive differences in binding affinities for ER-alpha receptors (17alpha E2 is 2-3x stronger) vs ER-beta receptors.

ER-alpha and ER-beta tend to antagonize each other. The most obvious example is the bone. Based on the studies on the mechanisms in rats - long-term consequences of high 17-beta-E2 with ER-alpha resistance should show much higher CV and bone disorder risk. We know ER-alpha is far more cardioprotective than ER-beta, and ER-beta is pro-arrhythmia. This seems to mostly explain why 17-alpha-E2 in male rats live longer.

We already have a case report of a man in 20s with ER-alpha insensitivity (rare):

He had normal testosterone, early onset of osteoporosis (think unopposed ER-beta activation) in his 20s, insulin resistance, continued slow linear growth in height, and signs of potential infertility (low sperm count). Seems to fit what we expect based on rat studies.

Men all have 17 alpha E2 and 17 beta E2 in the system, more than a postmenopausal woman. Male fetuses have higher brain 17 beta E2 than female fetuses and are responsible for “masculinizing” gene epigenetic activation via demethylation. Best to not think of estrogen=female hormone, because there are different male specific “masculinity” effects, positive libido effects, pro-spermatogenesis effects, anti-obesity effects, and some “anti-estrogenic” effects depending on the estrogen dose, type, and where.

9 Likes

Very interesting, thanks!

1 Like

There are no trials partly because of very conflicting messages and exactly when estradiol can be useful as a protective factor against “aging”. But I can see why Dr. Miller felt 17 alpha estradiol specifically was totally worth the shot over a lot of other interventions that didn’t make the cut in the NIH NIA ITP to clear the field and subsequent further confirmation since the first run had some moderate anomalies in a few control groups. I initially had some hesitancy myself but the second run definitely put 17-alpha estradiol higher up on my priority to investigate with unneutered male dogs vs neutered male dogs prone to canine cognitive dysfunction because the effect size is way too large to ignore as opposed to say aspirin.

This review has a pretty deep dive, includes what I mean by conflicting messaging, and influenced a lot of what I thought about how 17-beta-estradiol vs 17-alpha-estradiol works for “anti-cognitive aging”. It includes what the evidence is for that proposed “healthy cell bias” hypothesis you mentioned.

4 Likes

Deep dive indeed, thanks for sharing, quite controversial still.

As for the ITP, any theory as to why 17aE2 works only in male mice? And you saw that this longevity enhancement was completely abolished when they removed testosterone form the male mice? Fascinating.

Here’s a recent restrospective study by Brinton looking at medical records. Some pretty compelling large population, association data set.

My AD mom had an oopherectomy at 42 (complete estrogen loss pre menopause) and no HT post. Hmmm…

Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy (2020)

5 Likes

As for the ITP, any theory as to why 17aE2 works only in male mice?

There are several male sex-specific actions of estradiol in the first place but I have no definitive answers in terms of a grand theory that encompasses all the effects. For example, estradiol suppresses activation of the “inflammasome” in male mice only.

And you saw that this longevity enhancement was completely abolished when they removed testosterone from the male mice?

See:

4 Likes

Re the study linked: “We tested whether these anti‐aging effects extend to anatomical and functional aging”

Sorry if I missed, but this study didn’t address lifespan? It dosent explain why abolishing testosterone reduces lifespan in 17a2 treated mice?

2 Likes

Did we miss this paper? (and yes, more good news on 17-alpha estradiol)…

Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α

17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17α-estradiol elicits these benefits remain unresolved. Herein, we show that 17α-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor α (ERα) to that of 17β-estradiol. In addition, we show that the ablation of ERα completely attenuates the beneficial metabolic effects of 17α-E2 in male mice. Our findings suggest that 17α-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17α-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17α-E2 are not limited to mice. Collectively, these studies suggest ERα may be a drug target for mitigating chronic diseases in male mammals.

Full Paper:

7 Likes

Any idea where we can get it? I have yet to see a vendor offer it.

2 Likes

The only two sources I know - reputable lab/chemical supply companies (need to know someone who runs a chemistry/biology lab, or related company) but I’d be sure to avoid any Chinese suppliers (see messages from one user’s experience earlier in this thread), or:

5 Likes

One other idea - contact this company and try to get into the clinical trials:

17a Estradiol´s Application in Humans

We at Apollo Health Ventures are very optimistic, given that 17-α estradiol is one of only a handful of drugs that caused life extension in ITP trials. Due to the promising results in animals Apollo Health Ventures (Apollo.vc) has started the company Apollo Alpha Inc. and is currently working on developing 17-α estradiol as a human drug.

5 Likes